Overview of Skelaxin

Quick Facts

Property	Description
Active ingredient	Metaxalone
Form	Immediate-release oral tablet
Pharmacological class	Centrally acting skeletal muscle relaxant (SMR)
General use	Adjunct to rest/therapy for muscle spasm
Origin	Synthetic, Oxazolidinone derivative

What Type of Medicine is Skelaxin?

Skelaxin is the trade name for a prescription drug whose sole active component is Metaxalone, a single-ingredient, synthetic medication. Chemically, Metaxalone is defined as an Oxazolidinone derivative. It is formally classified as a centrally acting skeletal muscle relaxant (SMR), which means its therapeutic effect is achieved by influencing the brain and spinal cord—the Central Nervous System (CNS)—to help ease muscle over-activity. This classification confirms that the drug operates by affecting nerve signaling rather than acting directly on muscle tissue itself. A key differentiating feature is that Metaxalone is often noted to have a lower potential for sedation compared to some older SMRs.

Composition, Form, and General Purpose

The medication is supplied as an immediate-release oral tablet, consisting of the active ingredient Metaxalone combined with standard solid oral excipients. Skelaxin is formally indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. This usage is recognized for situations involving sudden muscle tightness or strain. The drug's general purpose is to alleviate this discomfort by producing a generalized, mild calming effect on the CNS. This action helps disrupt the cycle of pain and involuntary muscle tightening, thereby supporting the patient's ability to engage in necessary therapeutic activities and facilitating recovery.

What side effects are possible with Skelaxin?

Possible side effects and safety information

The safety profile of Skelaxin (metaxalone) is characterized by effects primarily related to its action on the Central Nervous System (CNS). The adverse reactions are classified and documented in official prescribing information according to the systems they affect and their frequency of occurrence.

Adverse Reactions Scope

The most frequent reactions officially listed in regulatory documents include CNS effects such as drowsiness, dizziness, and headache, along with psychiatric effects like nervousness or irritability. Gastrointestinal reactions, including nausea, vomiting, and general upset, are also commonly reported. Other documented adverse reactions fall into the following system categories:

Hematologic: Leukopenia and hemolytic anemia.
Hepatobiliary: Jaundice (yellowing of the skin or eyes).
Immune System: Hypersensitivity reactions, rash, and rare reports of anaphylaxis.

Serious Safety Considerations

The labeling includes warnings regarding conditions that can be clinically significant. Serotonin Syndrome, a potentially life-threatening condition, has been reported, particularly during concomitant use with other serotonergic drugs. CNS depression is a notable risk, which may be exacerbated when the medicine is taken with other CNS depressants, such as alcohol or opioids. Monitoring for these effects is highlighted, especially during treatment initiation and dosage increases.

Population-Specific Safety Restrictions

Metaxalone is contraindicated for use in individuals with known hypersensitivity to any component, a known tendency to drug-induced anemias, or with significantly impaired renal or hepatic function. Older patients are noted to be potentially more susceptible to the CNS depressant effects. Safety during pregnancy has not been established and its use is generally discouraged.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on descriptions and instructions documented in official government regulatory sources for Metaxalone (Skelaxin) regarding overdose.

Documented Overdose Manifestations

An overdose of metaxalone primarily affects the Central Nervous System (CNS) and may involve systemic and metabolic findings. Officially documented manifestations range from drowsiness and dizziness to coma and tonic-clonic seizures in severe cases. Other documented clinical signs include nausea, vomiting, hypothermia, metabolic acidosis, leukopenia, and hemolytic anemia.

Severe Outcome	Description
Cardiopulmonary Risk	Potential for respiratory depression and cardiovascular collapse is noted in massive overdoses.
Antidote Status	No specific antidote is known for metaxalone overdose.

Emergency Actions and Required Intervention

Regulatory guidance mandates that immediate medical attention must be sought if an overdose is suspected, due to the risk of severe and life-threatening outcomes. Management of an overdose is symptomatic and supportive. Supportive procedures may include gastric lavage followed by activated charcoal for recent ingestion to limit drug absorption. Patients require prolonged hospital monitoring to manage ongoing risks, particularly CNS depression and cardiovascular instability.

Therapeutic Uses of Skelaxin

What Skelaxin Treats: Main Uses and Benefits

The primary therapeutic role of Skelaxin (metaxalone) is the supportive management of symptoms related to physical discomfort arising from sudden muscle injury. The medication is used for conditions presenting with acute, painful musculoskeletal episodes.

The medicine may be part of symptomatic management when conditions involve episodic or fluctuating manifestations such as involuntary muscle spasm, muscle tension, and associated rigidity. It is applied in clinical settings that involve acute symptom patterns, acting as an adjunct to rest, physical therapy, and other supportive measures.

“Offering symptomatic relief helps patients cope more steadily with difficult episodes and supports the patient’s ability to engage with therapeutic recovery activities.”

The medication is relevant for easing the overall burden of symptoms following muscle strains, sprains, and local musculoskeletal injuries. It contributes to improved comfort during symptomatic periods, which supports maintaining functional stability.

Quick Fact: Relief for Acute Musculoskeletal Discomfort

Eligibility and Restrictions for Use

The eligibility profile for Skelaxin (metaxalone) is determined by official regulatory classifications that define who is permitted to use the medicine and who is strictly excluded.

Population Status	Regulatory Rule
Allowed Use	Adults and adolescents 13 years of age and older.
Use Not Established	Children 12 years of age and younger (safety and effectiveness have not been established).
Use with Caution	Geriatric patients (older adults) and those with mild to moderate hepatic or renal impairment.
Contraindicated	Patients with severe hepatic or renal impairment.

The drug is contraindicated and must not be used by anyone with a known hypersensitivity to its components. Furthermore, official labeling prohibits use in patients with a known tendency toward certain blood disorders, specifically drug-induced, hemolytic, or other anemias. Regarding reproductive status, regulatory documents state no available data exist to evaluate risk in pregnant patients, and it is unknown if the drug is secreted into human milk. Use is therefore conditional upon individual assessment and is defined by the absence of established safety data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Metaxalone (Skelaxin), defined primarily by additive pharmacodynamic effects and altered pharmacokinetics with food.

Documented Interaction Categories

Interaction Type	Interacting Substance/Condition	Regulatory Outcome
Pharmacodynamic	CNS Depressants (including alcohol)	Additive sedative effects may increase the risk of sedation and respiratory depression.
Pharmacodynamic	Serotonergic Drugs	Use has resulted in serotonin syndrome.
Pharmacokinetic	High-Fat Meal (Food)	Significantly increases drug exposure ( C max by up to 194% and AUC), which may enhance CNS depression.
Population Restriction	Severe Hepatic/Renal Impairment	Contraindicated due to risk of accumulation and enhanced drug effects.

Interaction Constraints and Notes

Co-administration with other CNS depressants or serotonergic agents is officially documented as resulting in pharmacodynamic additive effects that influence safety. The significant effect of food on metaxalone plasma concentrations represents a key pharmacokinetic interaction constraint. Metaxalone is metabolized in the liver, involving CYP enzymes such as CYP1A2, CYP2D6, CYP2E1, and CYP3A4, but is reported not to significantly inhibit or induce major CYP systems. Elderly patients may be especially susceptible to the enhanced CNS depression when the drug is taken with food. Additionally, use of metaxalone may cause false-positive results when performing the Benedict's test for reducing substances in urine.

Mechanism of Action

How Skelaxin (Metaxalone) Works Mechanistically

Metaxalone's pharmacological action is primarily mediated through its effect on the central nervous system (CNS). The precise molecular targets remain to be fully characterized, but its action involves a generalized CNS depressant effect on the brain and spinal cord, specifically at subcortical levels. This generalized depression modifies the excitability of neuronal pathways.

A key consequence of this CNS modulation is the inhibition of polysynaptic reflex arcs within the spinal cord. These complex pathways, involving multiple interneurons, are integral to generating elevated efferent (motor) outflow to skeletal muscle. By influencing the activity within these reflex pathways, metaxalone contributes to the suppression of signaling sequences that generate sustained, involuntary contractions. This mechanism defines the drug's effect on motor outflow without directly acting on the muscle contractile apparatus or the neuromuscular junction. The overall outcome is a modification of signaling patterns related to muscle hypertonicity.

Dosage and Administration Information

How Skelaxin (Metaxalone) is Used in Practice

Skelaxin (metaxalone) is an oral medication with standardized usage protocols. The sole route of administration is by mouth, using the immediate-release tablet formulation.

Standard Dosing and Frequency

The standard regimen for adults and pediatric patients 13 years of age and older involves taking a 800 mg tablet per dose. This quantity is taken on a multiple-times-daily schedule, specifically three or four times a day (TID or QID). The total amount of metaxalone taken should not exceed a maximum daily limit of 3200 mg. This frequency pattern is designed to maintain consistent exposure to the medicine throughout the day in line with the required short-term treatment course.

Administration Conditions and Duration

The administration of the tablet is flexible concerning meals; it may be taken with or without food. Taking the tablet with a high-fat meal can affect the drug’s absorption. Skelaxin is indicated for short-term use, serving as an adjunct to rest and physical therapy.

Population and Procedural Rules

Specific guidance exists for different populations. Safety and effectiveness are not established for use in pediatric patients under 12 years of age. Furthermore, a crucial procedural point is that the 800 mg formulation is not interchangeable on a milligram-to-milligram basis with the 640 mg metaxalone tablet, a detail that requires precise adherence to the prescribed strength.

Recent Clinical Evidence

The research base for Skelaxin (metaxalone) consists primarily of short-term randomized controlled trials (RCTs). These studies were applied in research contexts involving acute, painful musculoskeletal conditions, such as low-back pain, to explore how symptoms change over a defined time interval. Researchers primarily evaluated adult individuals who presented with acute muscle spasm and associated discomfort. The trials were designed to measure patient-reported outcomes describing perceived discomfort, including subjective pain intensity and functional measures like activity level. This research structure contributes to understanding short-term changes in symptoms during the study period.

A core component of the evidence involves double-blind, placebo-controlled studies. These comparative studies contribute to understanding the observed patterns of change in pain and functional measures when compared against an inactive control. Research has also evaluated whether the combination of metaxalone and common anti-inflammatory medications was associated with different short-term measurements than the anti-inflammatory alone. Overall, the certainty of the evidence remains low for the drug class, and systematic reviews research describes the need for more consistent data when evaluating metaxalone against placebo.

The majority of research consists of short-term studies, generally spanning seven days or up to two weeks. This means that evidence for long-term outcomes are not fully established, and research provides limited information regarding durability or use extending beyond the typical two-week period. Furthermore, effectiveness in children 12 years of age and below has not been established in the research studied. Data for groups with pre-existing severe kidney or liver impairment remain insufficient, as these populations were generally excluded from initial clinical efficacy trials, contributing to the scientific uncertainty in these subgroups.

Frequently Asked Questions (FAQ)

Common questions about Skelaxin (FAQ)

Q: Is Skelaxin considered a type of opioid or narcotic?

A: Official regulatory classification confirms that metaxalone, the active ingredient in Skelaxin, is not listed as a federally controlled substance. This designation separates it legally from the classification used for opioids and narcotics.

Q: Is Skelaxin classified as a sedative or a skeletal muscle relaxant?

A: Metaxalone is formally classified as a centrally acting skeletal muscle relaxant. Its therapeutic effect on muscle over-activity is related to its generalized sedative properties that influence the central nervous system.

Q: Why do healthcare professionals prescribe Skelaxin for muscle discomfort?

A: The official indication states that Skelaxin is used as an adjunct to rest, physical therapy, and other measures. Its prescribed purpose is to relieve the discomfort associated with acute, painful musculoskeletal conditions.

Q: Can Skelaxin be used for long-term chronic pain management?

A: Official prescribing information states that metaxalone is indicated only for short-term use. This usage profile aligns with the drug's role as an adjunct for acute musculoskeletal discomfort, not for chronic pain management.

Q: Is a generic version of Skelaxin (metaxalone) currently available?

A: Yes, the active ingredient in Skelaxin, metaxalone, is available in generic formulations. Regulatory agencies, such as the FDA, list these generic products as therapeutically equivalent to the brand-name drug.

Q: How quickly should I expect Skelaxin to start working after I take it?

A: Official drug information indicates that the drug's concentration in the bloodstream typically peaks approximately three hours after it is taken on an empty stomach. This time frame reflects when the highest concentration of the drug is typically measured in the bloodstream in fasted adults.

Q: How long does the therapeutic effect of Skelaxin typically last in the body?

A: According to pharmacokinetic studies, the average terminal half-life of metaxalone is around 9 hours, though this can vary. The half-life is the time it takes for the concentration of the medicine in the body to reduce by half.

Q: Can Skelaxin affect my normal sleep schedule or patterns?

A: Official prescribing information notes that Skelaxin's action as a central nervous system (CNS) depressant can cause drowsiness and dizziness. Because of these effects, the medicine may influence a patient's sleep, concentration, or overall physical and mental capabilities.

Q: Does Skelaxin interact with common herbal supplements such as St. John's Wort?

A: Regulatory documents highlight a risk of interaction with serotonergic drugs, a category that includes certain herbal supplements. This combination has been associated with reports of a potentially severe condition called Serotonin Syndrome.

Q: Is there a chance that Skelaxin could result in a false positive on a standard drug test?

A: Official precautions state that metaxalone may cause a false-positive result specifically on the Benedict's test for reducing substances in urine. Official information states that a glucose-specific test can differentiate this finding from actual glucose presence.

Q: Does Skelaxin interact with hormonal birth control pills?

A: The regulatory information states that metaxalone is not reported to significantly interfere with the activity of the major CYP enzymes. These enzymes are commonly involved in how the body processes hormonal contraceptives.

Q: What signs indicate that a side effect from Skelaxin requires immediate medical attention?

A: Official regulatory warnings detail serious adverse events. These include symptoms of Serotonin Syndrome or a severe hypersensitivity reaction such as rash or swelling. These symptoms are officially listed as conditions that necessitate immediate medical evaluation.

Q: Are there any food products I should avoid while taking Skelaxin?

A: Official prescribing information indicates that taking the drug with a high-fat meal significantly increases the amount of metaxalone in the bloodstream. This increase in drug exposure may enhance central nervous system (CNS) effects like drowsiness.

Q: Are there any special warnings for people with diabetes when taking Skelaxin?

A: Official information notes that the use of Skelaxin may cause a false-positive result in the Benedict's test, which is sometimes used to monitor glucose levels in urine. This potential for test interference is noted in the official guidance.

Q: Can Skelaxin be taken by people who have a history of mood disorders like depression or anxiety?

A: The drug is documented to interact with serotonergic agents, including some used for mood disorders. Reports of Serotonin Syndrome resulting from these combinations exist in regulatory documents, which can be life-threatening.

Q: Are there different risk profiles or side effect rates noted for men versus women using Skelaxin?

A: Pharmacokinetic data shows differences in how the body handles the drug based on sex. The official label indicates that the bioavailability (the rate and extent of drug absorption) is significantly higher in females compared to males, and the half-life is also longer in females.

Q: Where can I find the official FDA or regulatory documents about Skelaxin?

A: Official prescribing information and drug labeling can be accessed on governmental websites. Authoritative sources include the National Institutes of Health (NIH) DailyMed and the U.S. Food and Drug Administration (FDA) drug label repository.

Q: What happens if you take too much Skelaxin?

A: Official regulatory warnings describe that accidental or deliberate overdose, especially when combined with other CNS depressants, has led to fatalities. Symptoms of overdose can include severe central nervous system depression, seizures, agitation, and respiratory depression.

Q: Is it possible to be allergic to the dyes or inactive ingredients in Skelaxin tablets?

A: The drug is contraindicated, meaning it must not be used, by anyone with a known hypersensitivity to any of the components in the product. This general prohibition applies to both the active ingredient and all inactive ingredients.

Q: How does Skelaxin affect coordination?

A: Loss of coordination, or incoordination, is listed in the warnings section as a potential symptom of Serotonin Syndrome. This is a serious condition that has been reported, particularly when Skelaxin is used with other specific medications.

Q: What should be done if a patient feels confused after taking Skelaxin?

A: Confusion is noted in regulatory warnings as a potential symptom of Serotonin Syndrome. Since this is a serious adverse condition reported in the official drug labeling, this symptom is listed as one that necessitates prompt medical evaluation.

How should Skelaxin be stored and disposed of?

Storage and Disposal Requirements for Skelaxin

Skelaxin (metaxalone) tablets must be stored according to specific environmental and container rules documented in the official regulatory labeling.

Required Storage Conditions

The medication requires storage at Controlled Room Temperature, defined as 20 to 25 C (68 to 77 F), with protection from excessive heat and moisture. It is mandatory that the tablets be kept from freezing. Skelaxin must be stored in a tightly closed, light-resistant container, often the original packaging, and must always be kept out of the reach of children.

Official Disposal Instructions

Disposal of unused or expired Skelaxin should preferably be handled through an official drug take-back program. If a take-back program is not available, regulatory guidelines permit disposing of the product in household trash after mixing the tablets with an unappealing substance, such as dirt or used coffee grounds, and sealing the mixture in a container.

Skelaxin